Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

ARMOR Phase 3 Study
May. 9, 2023

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Read More
May. 4, 2023

Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

Read More
Mar. 29, 2023

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Read More